CClinicalTrials.gg
Status unknownNCT04352634HEROESUpdated Apr 1, 2021

The Covid-19 HEalth caRe wOrkErS (HEROES) Study

An observational study in Covid-19, Mental Health Disorder and Stress Disorder, sponsored by University of Chile. Status unknown at 22 sites in 21 countries. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-01.

Sponsored by University of Chile · Observational

The sponsor has not verified this record recently (last verified Mar 2021), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
2,000
Ages
18 Years and older
Sex
All
01

Study summary

Since December 2019 the world has been shaken with an enormous global threat: the Covid-19 pandemic. This new kind of coronavirus is generating an unprecedented impact both on the general population and on the healthcare systems in most countries. Health services are trying to expand their capacity to respond to the pandemic, taking actions such as increasing the number of beds; acquiring necessary equipment to provide intensive therapy (ventilators), and calling retired health professionals and health students so they can assist the overwhelmed health care workforce. Unfortunately, these organizational changes at health facilities, along with the fears and concerns of becoming ill with the virus or infecting their families, put an enormous emotional burden on workers in health services which may lead to negative outcomes on mental health in this population.

Recent cross-sectional studies in China indicate that health service workers exposed to people with Covid-19 reported higher rates of depressive and anxious symptoms. This negative impact on mental health among health workers in China has also been informally reported in other countries where the Covid-19 pandemic has been devastating in its effects (such as Spain and Italy), as well as in countries where the pandemic is becoming a growing public health problem. This is particularly relevant in regions with fewer resources (Latin America, North Africa), where there are limited means and the response from the health system is usually insufficient. Moreover, it is necessary to study these negative effects longitudinally considering that some effects will appear over time (post-traumatic stress).

The COVID-19 HEalth caRe wOrkErS (HEROES) study is a large, bottom-up, South-North initiative aimed to evaluate the impact of the COVID-19 pandemic on the mental health of health care workers (HCWs). HEROES encompasses a wide variety of academic institutions in 19 LMICs and 8 HICs, in partnership with the Pan American Health Organization (PAHO) and with support from the World Health Organization (WHO). The HEROES study is led by Dr. Rubén Alvarado at University of Chile, and Dr. Ezra Susser and Franco Mascayano at Columbia U Mailman School of Public Health.

Read the detailed description

Since December 2019 the world has been shaken with an enormous global threat: the Covid-19 pandemic. This new kind of coronavirus is generating an unprecedented impact both on the general population and on the healthcare systems in most countries. Health services are trying to expand their capacity to respond to the pandemic, taking actions such as increasing the number of beds; acquiring necessary equipment to provide intensive therapy (ventilators), and calling retired health professionals and health students so they can assist the overwhelmed health care workforce. Unfortunately, these organizational changes at health facilities, along with the fears and concerns of becoming ill with the virus or infecting their families, put an enormous emotional burden on workers in health services which may lead to negative outcomes on mental health in this population. Based on the literature to date, Covid-19 is significantly larger than previous pandemics in terms of the number of affected people worldwide, its spread across countries, its impact on healthcare systems and the severity of measures that have been taken by governments. Immediate consequences are palpable in the health care system. Many healthcare workers are overwhelmed by the increased workload; the lack of supplies and materials to provide appropriate treatment; the lack of clinical guidelines on prioritization and triage; and the increased feelings of isolation and loneliness. Previous research indicates that these negative effects can last over time and lead to the development of serious mental health problems such as post-traumatic stress disorder.

Recent cross-sectional studies in China indicate that health service workers exposed to people with Covid-19 reported higher rates of depressive and anxious symptoms. This negative impact on mental health among health workers in China has also been informally reported in other countries where the Covid-19 pandemic has been devastating in its effects (such as Spain and Italy), as well as in countries where the pandemic is becoming a growing public health problem. This is particularly relevant in regions with fewer resources (Latin America, North Africa), where there are limited means and the response from the health system is usually insufficient. Moreover, it is necessary to study these negative effects longitudinally considering that some effects will appear over time (post-traumatic stress). Also, it is necessary to take into account the nature and the extent of the health response (e.g., deployment, increased workload) in order to advance our understanding of these complex phenomenon and to inform policy and develop the kind of supports that this population deems useful.

The COVID-19 HEalth caRe wOrkErS (HEROES) study is a large, bottom-up, South-North initiative aimed to evaluate the impact of the COVID-19 pandemic on the mental health of health care workers (HCWs). HEROES encompasses a wide variety of academic institutions in 19 LMICs and 8 HICs, in partnership with the Pan American Health Organization (PAHO) and with support from the World Health Organization (WHO). The HEROES study is led by Dr. Rubén Alvarado at University of Chile, and Dr. Ezra Susser and Franco Mascayano at Columbia U Mailman School of Public Health.

Participants will complete an online questionnaire, which will be completely self-administered. It will take approximately 12 minutes and includes sociodemographic data, questions on work activity, training, fears and concerns related to Covid-19, as well as the GHQ-12 and a series of questions on other mental health issues (e.g., suicide, acute stress), resilience and psycho/social factors (e.g., formal and informal support).

02

Conditions studied

  • Covid-19
  • Mental Health Disorder
  • Stress Disorder
  • Anxiety
  • Depression
  • SARS-CoV-2

Keywords

  • Covid-19
  • healthcare professionals
  • mental health
  • pandemic
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

This study will include workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)

Inclusion criteria

  • Legal age
  • Currently working on a health service that provides care to COVID-19 patients
  • Give informed consent

Exclusion criteria

Exclusion Criteria:

  • Inability to use electronic devices (required to complete the survey)
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
2,000 participants (estimated)
Patient registry
No

Groups and cohorts

  • Healthcare workers

    Workers who interact with people with confirmed or suspected COVID-19 at different health services (primary care centers, emergency units, specialized care units, inpatient care units, critically ill patient units, among others). Potential participants will include any type of worker in these centers, including clinical and administrative staff, as well as supportive staff (e.g., food services)

    Other: Exposure to the SARS-CoV-2 and its consequences

Interventions

  • OtherExposure to the SARS-CoV-2 and its consequences

    This is an observational design. Participants are exposed to the SARS-CoV-2, the Covid-19 pandemic, and/or its consequences

05

What researchers measure

Primary outcomes

  1. Anxiety and depressive symptoms

    The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

    Time frame: 12 months

Secondary outcomes

  1. Experiences, fears and concerns about the Covid-19

    Ad hoc survey on experiences, fears, and concerns about Covid-19

    Time frame: Baseline

  2. Experiences, fears and concerns about the Covid-19

    Ad hoc survey on experiences, fears, and concerns about Covid-19

    Time frame: 3 months

  3. Experiences, fears and concerns about the Covid-19

    Ad hoc survey on experiences, fears, and concerns about Covid-19

    Time frame: 6 months

  4. Experiences, fears and concerns about the Covid-19

    Ad hoc survey on experiences, fears, and concerns about Covid-19

    Time frame: 12 months

  5. Training and resource prioritization

    Ad hoc survey on Covid-19 training and resource prioritization

    Time frame: Baseline

  6. Training and resource prioritization

    Ad hoc survey on Covid-19 training and resource prioritization

    Time frame: 3 months

  7. Training and resource prioritization

    Ad hoc survey on Covid-19 training and resource prioritization

    Time frame: 6 months

  8. Training and resource prioritization

    Ad hoc survey on Covid-19 training and resource prioritization

    Time frame: 12 months

  9. Suicide ideation (presence)

    Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

    Time frame: Baseline

  10. Suicide ideation (presence)

    Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

    Time frame: 3 months

  11. Suicide ideation (presence)

    Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

    Time frame: 6 months

  12. Suicide ideation (presence)

    Item from the Columbia Suicide Severity Rating Scale (C-SSRS) that measures suicidal ideation with a dichotomous answer (presence/absence)

    Time frame: 12 months

  13. Suicide ideation (frequency)

    5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

    Time frame: Baseline

  14. Suicide ideation (frequency)

    5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

    Time frame: 3 months

  15. Suicide ideation (frequency)

    5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

    Time frame: 6 months

  16. Suicide ideation (frequency)

    5-point Likert item from the Columbia Suicide Severity Rating Scale (C-SSRS). Higher scores indicate higher frequency.

    Time frame: 12 months

  17. Acute stress symptoms

    Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

    Time frame: Baseline

  18. Acute stress symptoms

    Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

    Time frame: 3 months

  19. Acute stress symptoms

    Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

    Time frame: 6 months

  20. Acute stress symptoms

    Ad hoc 3-item survey to evaluate acute stress disorder. Higher values of the 5-points Likert scales suggest higher frequency of symptoms

    Time frame: 12 months

  21. Psycho/social support and network

    Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

    Time frame: Baseline

  22. Psycho/social support and network

    Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

    Time frame: 3 months

  23. Psycho/social support and network

    Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

    Time frame: 6 months

  24. Psycho/social support and network

    Ad hoc survey on support network. The answers to the multiple items will be adjusted so higher values indicate higher levels of psychological and social support

    Time frame: 12 months

  25. Resilience

    The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

    Time frame: Baseline

  26. Resilience

    The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

    Time frame: 3 months

  27. Resilience

    The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

    Time frame: 6 months

  28. Resilience

    The Brief Resilience Scale (BRS) is a 6-item self-reported instrument that measures resilience. The range of scores is 6-30. Higher scores indicate higher resilience levels.

    Time frame: 12 months

  29. Anxiety and depressive symptoms

    The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

    Time frame: Baseline

  30. Anxiety and depressive symptoms

    The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

    Time frame: 3 months

  31. Anxiety and depressive symptoms

    The 12-item version of the General Health Questionnaire (GHQ-12) is a self-reported instrument that measures symptoms of anxiety and depression. It provides cut-off points to identify people at risk of anxiety and/or depression, which differ slightly between countries

    Time frame: 6 months

06

Study locations

11 of 22 sites recruiting
  • Columbia University
    New York, New York 10032, United States
    Active, not recruiting
  • Universidad del Chubut
    Rawson, Chubut 9103, Argentina
    • Marcela Inés Freytes Frey, PhD · Contact · mifreytesfrey@udc.edu.ar · 5492804263454
    • Rodrigo Ezequiel Jaldo, BsC · Contact · rejaldo@udc.edu.ar · 5493513908707
    • Marcela Inés Freytes Frey, PhD · Principal investigator
    • María Belén Pastrián, PhD · Sub investigator
    • Mónica Elba Borile · Sub investigator
    • Amanda Gotti · Sub investigator
    • María Verónica Vila · Sub investigator
    • Juliana Andrieu, PhD · Sub investigator
    • Marina Veleda · Sub investigator
    • Maura Rojas · Sub investigator
    • Cecilia Pedernera · Sub investigator
    • Leticia Macerla Baéz · Sub investigator
    • Soledad Fabiana Peña · Sub investigator
    • Marcelo Fabián Vaccaro · Sub investigator
    • Nancy Copa · Sub investigator
    • Cecilia Russo · Sub investigator
    • Paula Ulivarri · Sub investigator
    • Amelia Clark · Sub investigator
    • Virginia Jaime · Sub investigator
    • Laura Rojo · Sub investigator
    • María Virginia Jaime · Sub investigator
    • Efi Jockers · Sub investigator
    • Verónica Cuevas · Sub investigator
    • Víctor Igarribay · Sub investigator
    • Miguel Tolaba · Sub investigator
    Recruiting
  • National Institute of Health Named After Academician S. Avdalbekyan
    Yerevan, 0051, Armenia
    • Anna Isahakyan, MD · Contact · annaisahakian@gmail.com · +37499990074
    • Arin A Balalian, MD, MPH · Principal investigator
    • Anna Isahakyan, MD · Sub investigator
    • Khachatur Gasparyan, PhD · Sub investigator
    • Alexander Bazarchyan, MD, PhD · Sub investigator
    Recruiting
  • University of Sydney
    Sidney, New South Wales 2031, Australia
    • Clare A McCormack, PhD · Contact · cam2348@cumc.columbia.edu · 3477129331
    • Sonja Memedovic, PhD · Contact · s.memedovic@unsw.edu.au
    • Sonja Memedovic, PhD · Principal investigator
    • Clare McCormack, PhD · Sub investigator
    • Louisa Degenhardt, PhD · Sub investigator
    Not yet recruiting
  • Salud Global
    Sucre, Chuquisaca, Bolivia
    • María Teresa Solís Soto, MD, PhD · Contact · maritesolissoto@gmail.com · 59173295148
    • Armando Basagoitia Echalar, MD, MsC · Contact · armando.basagoitia@gmail.com · 59170324803
    • María Teresa Solís Soto, MD, PhD · Principal investigator
    • Armando Basagoitia Echalar, MD, MsC · Sub investigator
    • Víctor Estrada, MD, MsC · Sub investigator
    Not yet recruiting
  • University of Chile
    Santiago, Chile
    • Rubén Alvarado, PhD · Contact · ralvarado@med.uchile.cl · +56 2 2978 6967
    • Sara Schilling, MPH · Sub investigator
    • Eric Tapia, MPH · Sub investigator
    • Ruben Alvarado, PhD · Principal investigator
    Not yet recruiting
  • Universidad Nacional de Costa Rica
    Heredia, 863000, Costa Rica
    • Iliana Araya Ramírez, MD, PhD · Contact · iliana.araya.ramirez@una.cr · 50683897058
    • María Chaves Villalobos, MsC · Contact · maria.chaves.villalobos@una.cr · 50688865120
    • Juan José Romero Zúñiga, PhD · Principal investigator
    • Marianela Rojas Garbanzo, PhD · Sub investigator
    • Iliana Araya Ramírez, PhD · Sub investigator
    • María Chaves Villalobos, MsC · Sub investigator
    • Alejandra Gamboa Jiménez, MD · Sub investigator
    • Omar Barrantes Sotela, MsC · Sub investigator
    • Raúl Ortega Moreno, MsC · Sub investigator
    • Zaida Salazar Mora, MD · Sub investigator
    Not yet recruiting
  • Society for Emergecy and Disaster Medicine CzMA JEP
    Kladno, Bohemia 27201, Czechia
    • Jana Seblova, MD, PhD · Contact · seblo@volny.cz · 00420724568877
    • Jana Seblova, MD, PhD · Principal investigator
    • Dominika Seblova, PhD · Sub investigator
    • Dita Protopovová, MD, PhD · Sub investigator
    • Roman Gregor, MD, MBA · Sub investigator
    Recruiting
  • Hochschule Emden/Leer
    Emden, Niedersachsen 26723, Germany
    • Jutta Lindert, MD, PhD · Contact · Jutta.Lindert@hs-emden-leer.de · 00491774158919
    • Marta Natan · Contact
    • Jutta Lindert, MD, PhD · Principal investigator
    • Marta Natan · Sub investigator
    • Felix Sisenop · Sub investigator
    Recruiting
  • Centro de Investigaciones de las Ciencias de la Salud -CICS- Facultad de Ciencias Médicas Universidad de San Carlos de Guatemala -USAC-
    Guatemala City, 01011, Guatemala
    • Dorian E Ramírez Flores, MD, MsC · Contact · dramirez2198@medicina.usac.edu.gt · 50224187459
    • Víctor Puac-Polanco, MD, MsC · Contact · vdp2105@cumc.columbia.edu · 50224187459
    • Víctor Puac-Polanco, MD, MsC · Principal investigator
    • Alejandra Paniagua-Avila, MD, MPH · Sub investigator
    • Aida Barrera, MD, MsC · Sub investigator
    • Erwin Calgua Guerra, MD, MsC · Sub investigator
    • Dorian Ramírez Flores, MD, MsC, MPH · Sub investigator
    Recruiting
  • University of Cagliari
    Cagliari, CA 09124, Italy
    • Maria Francesca Moro, MD · Contact · mm4640@cumc.columbia.edu · +390706093498
    • Mauro Giovanni Carta, MD · Contact · maurogcarta@gmail.com · +390706093498
    • Maria Francesca Moro, MD · Principal investigator
    • Mauro Giovanni Carta, MD · Sub investigator
    • Peter K Kurotschka, MD · Sub investigator
    Recruiting
  • University of Cagliari
    Cagliari, Italy
    • Francesca Moro, MD · Contact · mm4640@cumc.columbia.edu
    • Mauro Carta, MD · Sub investigator
    • Francesca Moro, MD · Principal investigator
    Not yet recruiting
  • The Institute for Development Research Advocacy and Applied Care (IDRAAC)
    Beirut, 11002110, Lebanon
    • Elie Karam, MD · Contact · egkaram@idraac.org · 9611583583
    • Georges Karam, MD · Contact · georges.karam@idraac.org · 9611583583
    • Elie Karam, MD · Principal investigator
    • Georges Karam, MD · Sub investigator
    • Rachad Rayess, MD · Sub investigator
    • Rita Khoury, MD · Sub investigator
    • Aimée Karam, PhD · Sub investigator
    • Caroline Cordahi, DEA · Sub investigator
    • Youmna Cassir, DESS · Sub investigator
    • Zaher Krayem, PhD · Sub investigator
    • Dahlia Saab, MPH · Sub investigator
    Not yet recruiting
  • Logotipo del comercio Instituto Jalisciense De Salud Mental (SALME)
    Guadalajara, Jalisco 45170, Mexico
    • Jaime Carmona Huerta, MD, PhD · Contact · drjcarmonah@gmail.com · 3322562339
    • Allen Akcel Rodríguez, BsC · Contact · allen-ar@hotmail.com · 3313585332
    • Sol Durand Arias, MD, MsC · Principal investigator
    • Jaime Carmona Huera, MD, PhD · Sub investigator
    • Allen Ackel Rodriguez, BsC · Sub investigator
    Recruiting
  • Maastricht University
    Maastricht, Limburg 6229, Netherlands
    • Els van der Ven, PhD · Contact · elsjevanderven@gmail.com · +17185367406
    • Els van der Ven, PhD · Principal investigator
    • Bart Rutten, MD, PhD · Sub investigator
    • Frederike Schirmbeck, PhD · Sub investigator
    • Nikki Lee, PhD · Sub investigator
    • Afra van der Markt, MD · Sub investigator
    Not yet recruiting
  • University of Ibadan
    Ibadan, Oyo State 200220, Nigeria
    • Oye Gureje, MD, PhD · Contact · oye_gureje@yahoo.com · +2348033464284
    • Olatunde Ayinde, MD, MsC · Contact · oayinde@brandeis.edu · +2348032107441
    • Oye Gureje, MD, PhD · Principal investigator
    • Olatunde Ayinde, MD, MsC · Sub investigator
    Not yet recruiting
  • Ponce Health Sciences University
    Ponce, 00716, Puerto Rico
    • Eliut Rivera-Segarra, PhD · Contact · elrivera@psm.edu · 7874596312
    • Eliut Rivera-Segarra, PhD · Principal investigator
    • Malynie Blanco, MD · Sub investigator
    • Mirna Luz Arroyo Miranda, PhD, JD · Sub investigator
    • Irma Torres, PsyD · Sub investigator
    • Alíxida Ramos-Pibernus, PhD, MRC · Sub investigator
    • Normarie Torres-Blasco, PhD · Sub investigator
    • Ernesto Rosario-Hernández, PhD · Sub investigator
    Recruiting
  • King Abdullah International medical research center
    Riyadh, Central 11522, Saudi Arabia
    • Lubna Alnasser, MsC · Contact · la2580@cumc.columbia.edu · 00966504468135
    • Sulainam Alghnam, PhD · Contact · alghnams@ngha.med.sa · 00966539468887
    • Sulaiman Alghnam, PhD · Principal investigator
    • Lubna Alnasser, BDS, MPH · Sub investigator
    Not yet recruiting
  • Hospital La Paz Institute for Health Research (IdiPAZ)
    Madrid, 28046, Spain
    • Roberto Mediavilla, PhD · Contact · roberto.mediavilla@idipaz.es · +347270000
    • Eduardo Fernández-Jiménez, PhD · Contact · efjimenez@salud.madrid.org · +347270000
    • Maria-Fe Bravo-Ortiz, MD, PhD · Principal investigator
    • Eduardo Fernández-Jiménez, PhD · Sub investigator
    • Gonzalo Martínez-Alés, MD · Sub investigator
    • Roberto Mediavilla, PhD · Sub investigator
    Recruiting
  • Razi Hospital La Manouba
    Tunis, La Manouba, Tunisia
    • Uta Ouali, MD · Contact · uta.ouali@gmail.com · +21623266078
    • Fethi Nacef, MD · Contact · fethi.nacef@yahoo.fr · +21698302065
    • Uta Ouali, MD · Principal investigator
    • Fethi Nacef, MD · Sub investigator
    • Amira Jamoussi, MD · Sub investigator
    • Dorra Khattech, MsC · Sub investigator
    Recruiting
  • Koc University
    Istanbul, Sariyer 34450, Turkey
    Active, not recruiting
  • PNFA Salud Colectiva Instituto de Altos Estudios Dr Arnoldo Gabaldon
    Maracay, Aragua 2103, Venezuela
    • Ana Maria Rodrigues Rodrigues, MsC · Contact · anamrodrigues1985@gmail.com · +5804264325417
    • Juan Quintana, MsC · Contact · juanadrian1@yahoo.es · +5804166467999
    • Ana Maria Rodrigues Rodrigues, MsC · Principal investigator
    • Juan Quintana, PhD · Sub investigator
    • Francis Saavedra, MsC · Sub investigator
    • Julián Díaz, MsC · Sub investigator
    • Pedro Alcalá, PhD · Sub investigator
    • Oscar Feo, MsC · Sub investigator
    Recruiting
07

References and documents

Publications

  • Brooks SK, Webster RK, Smith LE, Woodland L, Wessely S, Greenberg N, Rubin GJ. The psychological impact of quarantine and how to reduce it: rapid review of the evidence. Lancet. 2020 Mar 14;395(10227):912-920. doi: 10.1016/S0140-6736(20)30460-8. Epub 2020 Feb 26. PubMed 32112714 ↗
  • Nacoti M, et al. At the Epicenter of the Covid-19 Pandemic and Humanitarian Crises in Italy: Changing Perspectives on Preparation and Mitigation. NEJM Catalyst, 2020;1(2)
  • Huang L, Lei W, Xu F, Liu H, Yu L. Emotional responses and coping strategies in nurses and nursing students during Covid-19 outbreak: A comparative study. PLoS One. 2020 Aug 7;15(8):e0237303. doi: 10.1371/journal.pone.0237303. eCollection 2020. PubMed 32764825 ↗
  • Lai J, Ma S, Wang Y, Cai Z, Hu J, Wei N, Wu J, Du H, Chen T, Li R, Tan H, Kang L, Yao L, Huang M, Wang H, Wang G, Liu Z, Hu S. Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Netw Open. 2020 Mar 2;3(3):e203976. doi: 10.1001/jamanetworkopen.2020.3976. PubMed 32202646 ↗

Individual participant data

Plan to share: Undecided

08

Registry details

Key details

Study ID
NCT04352634
Lead sponsor
University of Chile
Collaborators
Columbia University
Responsible party
Rubén Alvarado (PhD, University of Chile) — Principal investigator
First posted
Apr 20, 2020
Start date
Apr 26, 2020
Primary completion
Dec 31, 2021 (estimated)
Completion
Dec 31, 2021 (estimated)
Last update
Apr 1, 2021

Study contacts

Rubén Alvarado, PhD
Contact
ralvarado@med.uchile.cl
+56 2 2978 6967
Rubén Alvarado, PhD
principal investigator · University of Chile [Universidad de Chile]
Ezra Susser, MD DrPH
principal investigator · Columbia University
Franco Mascayano, MPH
principal investigator · Columbia Universty

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion